The price of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares last traded on Wall Street fell -1.83% to $2.14.
Based on available information, 2 analysts follow AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $80.00 and a low of $80.00, we find $80.00. Given the previous closing price of $2.18, this indicates a potential upside of 3569.72 percent. ACRX stock price is now -4.69% away from the 50-day moving average and -47.55% away from the 200-day moving average. The market capitalization of the company currently stands at $16.33M.
Among analysts, 1 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $80.00 as their price target over the next twelve months.
On November 11, 2019, Credit Suisse Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock reducing its target price from $7 to quote $2, while the Credit Suisse previously rated the stock as ‘Outperform’ on August 05, 2019.
In other news, Angotti Vincent J., Chief Executive Officer bought 46,400 shares of the company’s stock on Jun 07. The stock was bought for $10,333 at an average price of $0.22. Upon completion of the transaction, the Chief Executive Officer now directly owns 1,016,919 shares in the company, valued at $2.18 million. Insiders disposed of 141,966 shares of company stock worth roughly $0.3 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACRX stock. A new stake in AcelRx Pharmaceuticals Inc. shares was purchased by TANG CAPITAL MANAGEMENT LLC during the first quarter worth $42,000. MILLENNIUM MANAGEMENT LLC invested $21,000 in shares of ACRX during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in AcelRx Pharmaceuticals Inc. valued at approximately $12,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in ACRX for approximately $7,000. GOLDMAN SACHS GROUP INC purchased a new stake in ACRX valued at around $7,000 in the second quarter. In total, there are 63 active investors with 12.40% ownership of the company’s stock.
A candlestick chart of AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) showed a price of $2.2000 on Tuesday morning. During the past 12 months, AcelRx Pharmaceuticals Inc. has had a low of $1.76 and a high of $10.20. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 1.60, and a quick ratio of 1.50. The fifty day moving average price for ACRX is $2.2454 and a two-hundred day moving average price translates $4.0781 for the stock.
The latest earnings results from AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $9.6, beating analysts’ expectations of -$1.5 by 11.1. This compares to -$1.41 EPS in the same period last year. The company reported revenue of $0.51 million for the quarter, compared to $1.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -72.77 percent. For the current quarter, analysts expect ACRX to generate $620k in revenue.
AcelRx Pharmaceuticals Inc.(ACRX) Company Profile
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.